newswire, breaking biotechnology and pharma news

Friday, October 22, 2010 - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Adds Boston Bruins as Latest High Profile ViraTech UV-400 Customer - Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Adds Boston Bruins as Latest High Profile ViraTech UV-400 Customer

CENTERVILLE, MA – October 22, 2010 -( Newswire, – UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.

“This is the second professional hockey team to put the UV-400 in their locker rooms, along with several college hockey teams,” stated Charles Gulteri, President of NESSI. “Teams at this level of competition are acutely aware that healthy players are critical for a winning effort. Losing key players in-season for several games due to sickness that could have been avoided is costly and needs to be prevented using every effective tool commercially available. The ViraTech UV-400 kills bacteria and other contaminants, which are rampant in locker rooms, as well as controlling odors. The UV-400’s ability to dramatically reduce odors is a really helpful benefit in the close quarters of a locker room, especially given the access commonly granted to reporters and other special guests. We think this unit could become standard operating equipment in locker rooms around the world.” said Mr. Gulteri.

“Athletic locker rooms are becoming a surprisingly robust area of interest for our product,” said Jack Lennon, President of UV Flu Technologies. “Players are travelling by plane constantly, so they are very susceptible to respiratory illnesses that they pick up while travelling and then pass on by sneezing and coughing in the locker room. Not only does this cause other players to get sick, the illness can be inflamed by the many volatile organic compounds used in the locker rooms, from rubbing alcohol, through muscle relaxants, bathroom cleaning solvents, etc. The UV-400 kills over 99% of airborne bacteria and other contaminants with every pass, while also dramatically reducing the concentration and effect of these volatile organic compounds, including odors. We believe the market for our product in this market segment, along with our ongoing sales to the hotel and medical community may compel us to pro-actively increase our production estimates for the UV-400 over the next 18 months,” said Mr. Lennon.

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: For sales:

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC’s (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: For sales:

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838

SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on
( please read disclosure and disclaimers )
Visit the showcase page on
Request info :

Research more biotech stocks at the Biotech stocks Directory:

About is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. is known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: is a global meeting place for investors and industry following the sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

C Van Zant: 800-665-0411 -

Source -

No comments:

Post a Comment